| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| BeOne Medicines Ltd. | Pamiparib (BGB-290) | Maintenance Therapy Ovarian Cancer | Phase 3 | Oral | Oncology | |
| BeOne Medicines Ltd. | Tislelizumab - (RATIONALE 303) | Non-small cell lung cancer (NSCLC) | Phase 3 | Intravenous | Oncology | |
| BeOne Medicines Ltd. | Tislelizumab | Squamous non-small cell lung cancer (NSCLC) | Phase 3 | Intravenous | Oncology | |
| BeOne Medicines Ltd. | Tislelizumab - (RATIONALE 309) | Nasopharyngeal cancer (RM-NPC) | Phase 3 | Intravenous | Oncology | |
| BeOne Medicines Ltd. | Tislelizumab and chemotherapy - (RATIONALE 304) | Non-squamous non-small cell lung cancer (NSCLC) | Phase 3 | Intravenous | Oncology | |
| BeOne Medicines Ltd. | Tislelizumab and chemoradiotherapy | Esophageal squamous cell carcinoma (ESCC) | Phase 3 | Trial Completed | Intravenous | Oncology |
| BeOne Medicines Ltd. | Sonrotoclax (sonro) in combination with zanubrutinib (zanu) | Chronic lymphocytic leukemia/small lymphocytic leukemia, relapsed/refractory (R/R) mantle cell lymphoma (MCL) | Phase 3 | Trial Planned | Oral | Oncology |
| BeOne Medicines Ltd. | Tislelizumab plus platinum-based doublet chemotherapy - (RATIONALE-315) | Stage II-IIIA non-small cell lung cancer (NSCLC) | Phase 3 | Intravenous | Oncology |